Can a Two-Drug combo outsmart resistant ovarian cancer?

NCT ID NCT07741630

Not yet recruiting Disease control Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining two drugs—mirvetuximab soravtansine and suvemcitug—can help people with a type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 20 adults with FRα-positive, platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants will receive both drugs intravenously until their disease progresses or side effects become intolerable. The main goal is to see how long the treatment can keep the cancer from growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mirvetuximab soravtansine combined with suvemcitug
What this could lead to: If successful, this combination could offer a new treatment option for people with platinum-resistant ovarian cancer, potentially slowing tumor growth and improving outcomes.
What could go wrong: This is a small, early-phase trial, so results may not be conclusive. The combination may cause side effects or may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROC

More trials for these conditions

Other studies related to the condition(s) this trial covers.